Skip to main content Accesibility Help
×
×
Home

Impact of an Assay That Enables Rapid Determination of Staphylococcus Species and Their Drug Susceptibility on the Treatment of Patients with Positive Blood Culture Results

  • Mark Parta (a1) (a2), Melanie Goebel (a1), Jimmy Thomas (a1), Mahsa Matloobi (a1), Charles Stager (a1) (a2) and Daniel M. Musher (a1) (a2)...
Extract
Objective.

To determine whether an earlier determination of staphylococcal species and their antibiotic susceptibility decreases unnecessary antistaphylococcal treatment and/or facilitates earlier appropriate treatment.

Methods.

We used the Xpert MRSA/SA BC system (Cepheid) for immediate determination of species and their drug susceptibility in patients whose blood cultures revealed gram-positive cocci in clusters. We compared the treatment of patients whose physicians received early notification of these results (group 1) with the treatment of patients in a historical cohort with delayed reporting after traditional microbiological studies (group 2). Outcomes were analyzed according to whether blood culture was positive for Staphylococcus species other than S. aureus, methicillin-susceptible S. aureus (MSSA), or methicillin-resistant S. aureus (MRSA) and whether the drugs used were appropriate for methicillin-susceptible or methicillin-resistant staphylococci (hereafter referred to as “MSS drug” or “MRS drug” therapy, respectively).

Results.

There were 44 (76%) of 58 patients with bacteremia due to Staphylococcus species other than S. aureus in group 1 and 58 (55%) of 106 patients with bacteremia due to Staphylococcus species other than S. aureus in group 2 who received no antistaphylococcal antibiotics (P <.01). Five (6%) of 89 patients in group 1 and 31 (25%) of 123 patients in group 2 received 0-168 hours (0-7 days) of MRS drug therapy (P < .01). Among patients with MSSA bacteremia, the mean time to initiation of appropriate therapy was 5.2 hours in group 1 and 49.8 hours in group 2 (P < = .007). Excluding patients who received MRS drug therapy for unrelated conditions, the mean duration of treatment was 19.7 hours in group 1 and 80.7 hours in group 2 (P = .003). Six (50%) of the 12 patients in group 1 and 39 (81%) of the 48 patients in group 2 received MRS drug therapy for MSSA bacteremia (P = .025). Time to initiation of therapy for MRSA bacteremia did not differ between groups.

Conclusions.

The use of an assay with rapid results reduced the use of antistaphylococcal therapy among patients who did not have S. aureus bacteremia; it also decreased the use of MRS drug therapy and led to earlier appropriate therapy among patients with MSSA bacteremia.

Copyright
Corresponding author
Baylor College of Medicine, 1709 Dryden Road, Suite 6.12, MS: BCM 620.625, Houston, TX 77030, (parta@bcm.edu)
References
Hide All
1.Awad, SS, Palacio, CH, Subramanian, A, et al.Implementation of a methicillin-resistant Staphylococcus aureus (MRSA) prevention bundle results in decreased MRSA surgical site infections. Am J Surg 2009;198(5):607610.
2.Parta, M, Goebel, M, Matloobi, M, Stager, C, Musher, DM. Identification of methicillin-resistant or methicillin-susceptible Staphylococcus aureus in blood cultures and wound swabs by GeneXpert. J Clin Microbiol 2009;47(5):16091610.
3.Xpert MRSA/SA BC. Instruction manual. Sunnyvale, CA: Cepheid; 2008.
4.Chang, FY, Peacock, JE Jr, Musher, DM, et al.Staphylococcus aureus bacteremia: recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine (Baltimore) 2003;82(5):333339.
5.Kim, SH, Kim, KH, Kim, HB, et al.Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2008;52(1):192197.
6.Fang, CT, Shau, WY, Hsueh, PR, et al.Early empirical glycopeptide therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006;57(3):511519.
7.Gomez, J, Garcia-Vazquez, E, Banos, R, et al.Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis 2007;26(4):239245.
8.Kim, SH, Park, WB, Lee, KD, et al.Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004;54(2):489497.
9.Schramm, GE, Johnson, JA, Doherty, JA, Micek, ST, Kollef, MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006;34(8):20692074.
10.Kim, SH, Park, WB, Lee, CS, et al.Outcome of inappropriate empirical antibiotic therapy in patients with Staphylococcus aureus bacteraemia: analytical strategy using propensity scores. Clin Microbiol Infect 2006;12(1):1321.
11.Mason, EO, Lamberth, LB, Hammerman, WA, Hulten, KG, Versalovic, J, Kaplan, SL. Vancomycin MICs for Staphylococcus aureus varyby detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 2009;47(6):16281630.
12.Tenover, FC, Moellering, RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007;44(9):12081215.
13.Alos, JI, Garcia-Canas, A, Garcia-Hierro, P, Rodriguez-Salvanes, F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J Antimicrob Chemother 2008;62(4):773775.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

Infection Control & Hospital Epidemiology
  • ISSN: 0899-823X
  • EISSN: 1559-6834
  • URL: /core/journals/infection-control-and-hospital-epidemiology
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed